[Comparative clinical-economic analysis of antibiotic therapy in pyogenic inflammatory diseases of the lower extremities].
A randomized comparative investigation was carried out in two equal groups of patients with pyo-inflammatory diseases of lower extremities (the total number 50 patients) in order to study effectiveness and tolerance to Netilmycin (1st group) and Gentamycin (2nd group) given in combination with Cefasolin. Clinical symptoms were estimated immediately after operation, in 3, 6 and 10-12 days after it. Bacteriological investigations were fulfilled immediately after operation, in 72 h and in 6-10 days after the beginning of antibacterial therapy. Clinical and biochemical investigations of blood were fulfilled before and in 10 days after the beginning of the treatment. Effectiveness of the treatment in the first group was 100%, in the second group--80%. In the second group the antibiotics were changed in 20% of cases and the average duration of hospitalization among the patients of this group was reliably longer that in the first group. The eradication rating of Netilmycin was higher than that of Gentamycin (25 strains from 25 and 20 from 25 respectively). Gentamycin had a pronounced nephrotoxic effect (elevation of the level of creatinin and urea of blood in dynamics by 21% and 32%), as compared with Netilmycin (9% and 3%). Total expenses to antibiotic therapy in the first group made up 97,650 rub, and in the second group 106,245 rub. Netilmycin in combination with Cefasolin was more effective for acute pyo-inflammatory diseases of lower extremities than a combination of Gentamycin with Cefasolin, it more rapidly resulted in reduction of clinical signs of inflammation, was better endured and more economical.
Shliapnikov
S A
SA
Karpov
O I
OI
Oranskiĭ
I F
IF
Zaĭtsev
A A
AA
D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000191:economics* / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000188:drug therapy* / Q000191:economics*; D002437:Cefazolin / Q000191:economics / Q000627:therapeutic use; D003362:Cost-Benefit Analysis; D005260:Female; D005839:Gentamicins / Q000191:economics / Q000627:therapeutic use; D006801:Humans; D007249:Inflammation / Q000188:drug therapy / Q000191:economics; D035002:Lower Extremity; D008297:Male; D008875:Middle Aged; D009428:Netilmicin / Q000191:economics / Q000627:therapeutic use; D013492:Suppuration / Q000188:drug therapy / Q000191:economics; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents; D005839:Gentamicins; D009428:Netilmicin; D002437:Cefazolin
Sravnitel'nyĭ kliniko-ékonomicheskiĭ analiz programm antibiotikoterapii gnoĭno-vospalitel'nykh zabolevaniĭ nizhnikh konechnosteĭ.